Skip to main content
OpenTrials
Completed

NCT Number: NCT03842254

Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease

This study evaluates the effect of erythropoietin on the number and function of regulatory T cells in adults with autoimmune hepatitis. Participants will receive a single dose of erythropoietin, and then the investigators will collect blood at different time points for analysis of regulatory T cell number and function.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–74 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Northwestern Medicine, Chicago, Illinois, United States

Loading trial locations.

About this study

There is data from the laboratory that erythropoietin helps stimulate regulatory T cells, a type of immune cell which is thought to combat autoimmunity, but this study will look at whether it does the same thing in adults with autoimmune hepatitis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of autoimmune liver diseases (autoimmune hepatitis, autoimmune cholangiopathy, or primary biliary cirrhosis or primary sclerosing cholangitis with hepatic autoimmune liver disease or overlap syndrome) confirmed on liver biopsy
  • Use of immunosuppressive therapy (prednisone, azathioprine, 6-mercaptopurine, mycophenolate mofetil) for the treatment of the autoimmune liver disease
  • Stable immunosuppression regimen at least 6 months prior to enrollment
  • Ability to provide verbal and written informed consent

Exclusion criteria

  • Diagnosis of decompensated cirrhosis (defined by presence of ascites, varices, encephalopathy)
  • Hemoglobin above average normal value (15.7 g/dL in men, 13.8 g/dL in women)
  • Alanine aminotransferase greater than 2 times upper limit of normal (33 IU/L in men and 25 IU/L in women)
  • Uncontrolled hypertension with systolic blood pressure greater than or equal to 160 or diastolic blood pressure greater than or equal to 100
  • End-stage renal disease on hemodialysis
  • History of venous thromboembolism including deep vein thromboses or pulmonary emboli
  • History of stroke
  • History of heart failure
  • History of seizure disorder
  • History of significant cardiovascular disease including a history of myocardial infarction
  • Active malignancy (untreated or undergoing therapy)
  • History of pure red cell aplasia
  • History of intolerance or allergy to erythropoietin
  • Known hypersensitivity to mammalian cell-derived products
  • Known hypersensitivity to human albumin
  • Presence of vascular access
  • Prior recipient of erythropoietin within 12 weeks of the study
  • Patient unable to provide consent including infants, children, teenagers, prisoners, cognitively impaired adults
  • Non-English speaking
  • Pregnancy

Treatment and study plan

Erythropoietin

Drug

Subcutaneous injection of erythropoietin 10,000 units

Primary outcomes

  1. Change in number of regulatory T cells

    Time frame: At time of enrollment, then at 2 weeks, 4 weeks, and 12 weeks.

    Calculated relative to baseline collected at time of enrollment

Secondary outcomes

  1. Change in number of effector T cells after a single dose of erythropoietin

    Time frame: At time of enrollment, then at 2 weeks, 4 weeks, and 12 weeks.

    Calculated relative to baseline collected at time of enrollment

  2. Change in cytokine production by the T cells in response to ex vivo stimulation

    Time frame: At time of enrollment, then at 2 weeks, 4 weeks, and 12 weeks.

    Calculated relative to baseline collected at time of enrollment

Sponsors and collaborators

Lead sponsor

Northwestern University

Other

Collaborators

  • Icahn School of Medicine at Mount Sinai
  • Mount Sinai Hospital, New York

Registry information

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Feb 15, 2019
Registry last updated
Mar 4, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.